Lilly is aiming to strengthen its position as a leader in the obesity treatment market, which is expected to hit $150 billion ...

About 44% of U.S. employers with 500 or more employees cover drugs for weight loss in 2024, up from 41% in 2023, according to ...

Investors are fearful RFK Jr.'s critical stance on weight loss drugs could impact pricing or Medicare coverage, but BMO says ...

The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

In 2024, the percentage of U.S. employers covering weight-loss drugs has increased, with notable rises among larger employers ...

The only approved oral GLP-1 drug is Rybelsus, a pill for type 2 diabetes from Novo Nordisk, the same company that makes ...

Catalent is vulnerable to facility closures whether from natural disasters or manufacturing issues, and a warning letter from the FDA or other regulatory agency can result in manufacturing delays or ...

Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...

Novo Nordisk's blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles high rates of obesity.

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...

Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...